Literature DB >> 22871320

Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines.

Hélène Albert1, Eric Battaglia, Carolino Monteiro, Denyse Bagrel.   

Abstract

CDC25 (cell division cycle 25) phosphatases are essential for cell cycle control under normal conditions and in response to DNA damage. They are represented by three isoforms, CDC25A, B and C, each of them being submitted to an alternative splicing mechanism. Alternative splicing of many genes is affected in response to genotoxic stress, but the impact of such a stress on CDC25 splicing has never been investigated. In this study, we demonstrate that genotoxic agents (doxorubicin, camptothecin, etoposide and cisplatin), alter the balance between CDC25C splice variants in human breast cancer cell lines both at the mRNA and protein levels. This modulation occurs during the response to moderate, sub-lethal DNA damage. Our results also suggest that the CDC25C splice variants expression shift induced by a genotoxic stress is dependent on the ATM/ATR signaling but not on p53. This study highlights the modulation of CDC25C alternative splicing as an additional regulatory event involved in cellular response to DNA damage in breast cancer cells.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871320      PMCID: PMC5528395          DOI: 10.1016/j.molonc.2012.06.003

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  50 in total

1.  The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x.

Authors:  Lulzim Shkreta; Laetitia Michelle; Johanne Toutant; Michel L Tremblay; Benoit Chabot
Journal:  J Biol Chem       Date:  2010-10-27       Impact factor: 5.157

2.  Differential mitotic degradation of the CDC25B phosphatase variants.

Authors:  I Kieffer; C Lorenzo; C Dozier; E Schmitt; B Ducommun
Journal:  Oncogene       Date:  2007-06-25       Impact factor: 9.867

Review 3.  Cellular stress and RNA splicing.

Authors:  Giuseppe Biamonti; Javier F Caceres
Journal:  Trends Biochem Sci       Date:  2009-02-07       Impact factor: 13.807

4.  Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.

Authors:  Dawn S Chandler; Ravi K Singh; Lisa C Caldwell; Jaquelyn L Bitler; Guillermina Lozano
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

5.  Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.

Authors:  J Bartek; R Iggo; J Gannon; D P Lane
Journal:  Oncogene       Date:  1990-06       Impact factor: 9.867

6.  A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy.

Authors:  P G Komarov; E A Komarova; R V Kondratov; K Christov-Tselkov; J S Coon; M V Chernov; A V Gudkov
Journal:  Science       Date:  1999-09-10       Impact factor: 47.728

7.  An emerging role for nuclear RNA-mediated responses to genotoxic stress.

Authors:  Roberta Busà; Claudio Sette
Journal:  RNA Biol       Date:  2010-07-01       Impact factor: 4.652

8.  DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter.

Authors:  Selvon St Clair; Luciana Giono; Shohreh Varmeh-Ziaie; Lois Resnick-Silverman; Wen-Jun Liu; Abhilash Padi; Jayasri Dastidar; Andrea DaCosta; Melissa Mattia; James J Manfredi
Journal:  Mol Cell       Date:  2004-12-03       Impact factor: 17.970

9.  Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells.

Authors:  Stéphanie Solier; Amélie Lansiaux; Emmanuelle Logette; Jane Wu; Johann Soret; Jamal Tazi; Christian Bailly; Lydie Desoche; Eric Solary; Laurent Corcos
Journal:  Mol Cancer Res       Date:  2004-01       Impact factor: 5.852

10.  Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma.

Authors:  Junchao Guo; Jörg Kleeff; Junsheng Li; Jiayi Ding; Jürgen Hammer; Yupei Zhao; Thomas Giese; Murray Korc; Markus W Büchler; Helmut Friess
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

View more
  9 in total

1.  Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines.

Authors:  Hélène Albert; Eric Battaglia; Carolino Monteiro; Denyse Bagrel
Journal:  Mol Oncol       Date:  2012-07-27       Impact factor: 6.603

2.  Personalized characterization of diseases using sample-specific networks.

Authors:  Xiaoping Liu; Yuetong Wang; Hongbin Ji; Kazuyuki Aihara; Luonan Chen
Journal:  Nucleic Acids Res       Date:  2016-09-04       Impact factor: 16.971

3.  Myelodysplasia-associated mutations in serine/arginine-rich splicing factor SRSF2 lead to alternative splicing of CDC25C.

Authors:  Lindsey Skrdlant; Jeremy M Stark; Ren-Jang Lin
Journal:  BMC Mol Biol       Date:  2016-08-23       Impact factor: 2.946

4.  The Expression and Clinical Outcome of pCHK2-Thr68 and pCDC25C-Ser216 in Breast Cancer.

Authors:  Huayong Jiang; Bin Wang; Fuli Zhang; Yuanyu Qian; Chia-Chen Chuang; Mingzhen Ying; Yajie Wang; Li Zuo
Journal:  Int J Mol Sci       Date:  2016-10-28       Impact factor: 5.923

5.  Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma.

Authors:  Sunniva Stordal Bjørklund; Anshuman Panda; Surendra Kumar; Michael Seiler; Doug Robinson; Jinesh Gheeya; Ming Yao; Grethe I Grenaker Alnæs; Deborah Toppmeyer; Margit Riis; Bjørn Naume; Anne-Lise Børresen-Dale; Vessela N Kristensen; Shridar Ganesan; Gyan Bhanot
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

Review 6.  On Broken Ne(c)ks and Broken DNA: The Role of Human NEKs in the DNA Damage Response.

Authors:  Isadora Carolina Betim Pavan; Andressa Peres de Oliveira; Pedro Rafael Firmino Dias; Fernanda Luisa Basei; Luidy Kazuo Issayama; Camila de Castro Ferezin; Fernando Riback Silva; Ana Luisa Rodrigues de Oliveira; Lívia Alves Dos Reis Moura; Mariana Bonjiorno Martins; Fernando Moreira Simabuco; Jörg Kobarg
Journal:  Cells       Date:  2021-02-27       Impact factor: 6.600

7.  Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation.

Authors:  Jane Jialu Xu; Alistair M Chalk; Iva Nikolic; Kaylene J Simpson; Monique F Smeets; Carl R Walkley
Journal:  Blood Adv       Date:  2022-04-12

Review 8.  Molecular mechanisms of etoposide.

Authors:  Alessandra Montecucco; Francesca Zanetta; Giuseppe Biamonti
Journal:  EXCLI J       Date:  2015-01-19       Impact factor: 4.068

9.  Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells.

Authors:  Changyi Lin; Fu-Ju Chou; Jieyang Lu; Wanying Lin; Matthew Truong; Hao Tian; Yin Sun; Jie Luo; Rachel Yang; Yuanjie Niu; Rosa Nadal; Emmanuel S Antonarakis; Carlos Cordon-Cardo; Deepak Sahasrabudhe; Chi-Ping Huang; Shuyuan Yeh; Gonghui Li; Chawnshang Chang
Journal:  Aging (Albany NY)       Date:  2020-09-10       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.